Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is a rare hematodermic myeloid malignancy that is known to be derived from plasmacytoid dendritic cells which are characterized by expression of CD4, CD56, and more specific markers such as CD123. Here, the authors present three cases of BPDCN diagnosed in the past two years and address different available diagnostic modalities such as morphology, immunohistochemistry, flow cytometry, and cytogenetics. Overall, we believe that although BPDCN is a rare diagnosis, it should not be left unchecked. Currently, available immunophenotyping markers are of great help, but the main clue to figure out the problem of BPDCN is clinicopathologic suspicion.